Agilent Expects Varian to Add $111M to Life-Sci Arm's H2 Revenue, May Be a Year for Large M&A | GenomeWeb

This story originally ran on May 19.

By Tony Fong

Agilent Technologies expects its recently completed acquisition of Varian to add about $111 million to its Life Sciences business for the second half of fiscal 2010, company officials said this week.

As the company integrates the Varian business into its fold, Agilent CEO William Sullivan added that the company in one year "will be in a position to again look at [large M&A] opportunities."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.